Evidence map›Paper›PMID 29538707›Full record

ArticleJournal of the Pediatric Infectious Diseases Society2019

Serologic Detection of Antibodies Targeting the Leukocidin LukAB Strongly Predicts Staphylococcus aureus in Children With Invasive Infection.

James B Wood, Lauren S Jones, Nicole R Soper, Meng Xu, Victor J Torres, C Buddy Creech, Isaac P Thomsen

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the Pediatric Infectious Diseases Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Dissecting the Human Response toFrontiers in immunology · 2021
    Article
  4. New developments and future challenges in prevention, diagnosis, and treatment of prosthetic joint infection.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2020
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

James B WoodDivision of Pediatric Infectious Diseases, Department of Pediatrics, Nashville, Tennessee.
Lauren S JonesDivision of Pediatric Infectious Diseases, Department of Pediatrics, Nashville, Tennessee.
Nicole R SoperDivision of Pediatric Infectious Diseases, Department of Pediatrics, Nashville, Tennessee.
Meng XuDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Victor J TorresDepartment of Microbiology, New York University School of Medicine, New York.
C Buddy CreechDivision of Pediatric Infectious Diseases, Department of Pediatrics, Nashville, Tennessee.
Isaac P ThomsenDivision of Pediatric Infectious Diseases, Department of Pediatrics, Nashville, Tennessee.
New York University · USVanderbilt University · US

Funding

Mechanistic Studies Of The Staphylococcus aureus LukAB CytotoxinR01AI099394 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Victor J. Torres · 2013 to 2026
$6.1M
Childhood Infections Research ProgramT32AI095202 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JAMES E CASSAT · 2011 to 2026
$4.2M
Evaluating the Functional Antibody Response to Pediatric S. aureus InfectionsK23AI113150 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI THOMSEN, ISAAC P · 2014 to 2018
$887k
NIAID NIH HHS K23 AI113150NIAID NIH HHS R01 AI099394NIAID NIH HHS T32 AI095202
6 · The paper itself

Abstract

backgroundStaphylococcus aureus is among the most commonly identified causes of invasive bacterial infection in children; however, reliable results from cultures of sterile-site samples often cannot be obtained, which necessitates prescription of a broad empiric antimicrobial agent(s). Children with invasive S aureus infection rapidly generate high antibody titers to the cytotoxin LukAB; therefore, the aim of this study was to assess the diagnostic utility of an anti-LukAB antibody assay for children with musculoskeletal infection (MSKI).

methodsWe conducted a 2-year prospective study of all eligible children admitted to Vanderbilt Children's Hospital with an MSKI. Acute and convalescent sera were obtained, and antibodies that target LukAB were measured by an enzyme-linked immunosorbent assay.

resultsForty-two children were enrolled. The median concentrations of LukAB antibodies for children with S aureus infection were 130.3 U/mL in the acute phase and 455 U/mL in the convalescent phase (P < .001). The median concentrations of LukAB antibodies in children with a non-S aureus MSKI were 8.6 U/mL in the acute phase and 9.7 U/mL in the convalescent phase. The assay discriminated between S aureus and non-S aureus infection with areas under the receiver operating characteristic curve of 0.81 (95% confidence interval, 0.67-0.95; P < .001) and 0.95 (95% confidence interval, 0.86-1; P < .001) for samples tested in the acute and follow-up periods, respectively. With no false-negative results, the assay accurately ruled out S aureus in samples obtained during the convalescent phase.

conclusionCulture-independent diagnostics have the potential to improve care by narrowing antimicrobial therapy on the basis of the likelihood of S aureus infection. The results of this proof-of-concept study suggest that a LukAB serologic assay might be useful in the diagnosis of invasive bacterial infections, and larger-scale validation studies are warranted.

Indexed as

Antibodies, BacterialBacterial ProteinsChildChild, PreschoolEnzyme-Linked Immunosorbent AssayFemaleHistocompatibility Antigens Class IIHospitals, PediatricHumansImmunoglobulin GInfantLeukocidinsMaleMusculoskeletal DiseasesProspective StudiesStaphylococcal InfectionsAntibodies, BacterialBacterial ProteinsHistocompatibility Antigens Class IIImmunoglobulin Gleukocidin AB, Staphylococcus aureusLeukocidinsdiagnostic assayimmune responseLukABStaphylococcus aureus

Identifiers

PMID29538707
PMCPMC6510946
OpenAlexW2791199048

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.